Eli Lilly’s Mounjaro drug showed cardiovascular benefits in a head-to-head trial against Trulicity, reducing major adverse cardiovascular events by 8%. However, analysts were disappointed that Mounjaro did not show superiority over Trulicity. The trial involved 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

In the same trial, Mounjaro demonstrated a 28% reduction in major adverse cardiovascular events and a 39% decrease in all-cause mortality compared to a placebo. It also led to improvements in A1C, weight, and cardiovascular biomarkers. Notably, Mounjaro showed a 16% lower rate of all-cause mortality compared to Trulicity.

Eli Lilly and Company is a pharmaceutical company that develops and markets human pharmaceuticals globally. While the company’s stock, LLY, is considered a profitable growth stock, some analysts believe that other AI stocks offer greater potential. For more information on undervalued AI stocks, check out their free report on the best short-term AI stock.

Read more at Yahoo Finance: Eli Lilly’s Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial